raltegravir-O-methyl impurity

Raltegravir-O-methyl impurity is a structurally related impurity arising from methylation at the hydroxyl oxygen of the propoxy side chain in the parent antiretroviral agent raltegravir. This modification introduces a methoxy group, replacing the native hydroxyl, while retaining the naphthyridine core, cyclopropyl substituent, and piperazinyl-methylphenyl motif. The compound features an ether linkage at the site of modification, maintaining conjugation with the aromatic system. It serves as a critical HPLC reference standard for quantifying process-derived O-alkylation impurities in raltegravir active pharmaceutical ingredient batches.